zenodorestricted
Supplementary Figures for IJMS: Type II JAK2 inhibitor CHZ-868 and HSP-90 inhibitors are potent towards the ruxolitinib resistant JAK2 variants in JAK2 driven myeloproliferative neoplasms.
ShareScore
12/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 4
- Harmonization
- 0
- Access
- 8
- Reuse readiness
- 0
- Engagement
- 0
Dataset details
- Repository
- zenodo
- Published
- December 27, 2023
- License
- cc-by-4.0
- DOI
- 10.5281/zenodo.10438770
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.